GB0418388D0 - Cell therapy - Google Patents
Cell therapyInfo
- Publication number
- GB0418388D0 GB0418388D0 GBGB0418388.5A GB0418388A GB0418388D0 GB 0418388 D0 GB0418388 D0 GB 0418388D0 GB 0418388 A GB0418388 A GB 0418388A GB 0418388 D0 GB0418388 D0 GB 0418388D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- cell therapy
- treatment
- methods
- relates
- exo1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/11—Exodeoxyribonucleases producing 5'-phosphomonoesters (3.1.11)
- C12Y301/11001—Exodeoxyribonuclease I (3.1.11.1)
Abstract
The invention relates to cell therapy, and in particular to the use of exol gene and the EXO1 enzyme in medicine, and to the uses thereof in treatment and therapy of various diseases. In particular, the invention relates to the treatment or prevention of cancer and/or aging, and to methods of carrying out such methods, including recombinant constructs encoding EXO1.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0418388.5A GB0418388D0 (en) | 2004-08-18 | 2004-08-18 | Cell therapy |
PCT/GB2005/003211 WO2006018632A2 (en) | 2004-08-18 | 2005-08-17 | Cell therapy with exo 1 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0418388.5A GB0418388D0 (en) | 2004-08-18 | 2004-08-18 | Cell therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
GB0418388D0 true GB0418388D0 (en) | 2004-09-22 |
Family
ID=33042231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0418388.5A Ceased GB0418388D0 (en) | 2004-08-18 | 2004-08-18 | Cell therapy |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0418388D0 (en) |
WO (1) | WO2006018632A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008157747A1 (en) * | 2007-06-21 | 2008-12-24 | The Jackson Laboratory | Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders |
WO2009085216A2 (en) | 2007-12-20 | 2009-07-09 | Squicor | Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease |
EP2077335A1 (en) * | 2007-12-22 | 2009-07-08 | Universitätsklinikum Schleswig-Holstein | EXO1 promoter polymorphism associated with exceptional life expectancy in humans |
US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
WO2013090645A1 (en) * | 2011-12-13 | 2013-06-20 | Buck Institute For Research On Aging | Methods for improving medical therapies |
WO2013158664A2 (en) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
US10279018B2 (en) | 2012-12-03 | 2019-05-07 | Unity Biotechnology, Inc. | Immunogenic compositions for inducing an immune response for elimination of senescent cells |
TW201536324A (en) * | 2013-06-19 | 2015-10-01 | Buck Inst For Res On Aging | Methods for enhancing effectiveness of medical therapies |
US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
MX2016009753A (en) | 2014-01-28 | 2017-07-07 | Buck Inst For Res On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders. |
WO2017223107A1 (en) * | 2016-06-20 | 2017-12-28 | Unity Biotechnology, Inc. | Genome modifying enzyme therapy for diseases modulated by senescent cells |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6418294A (en) * | 1993-03-30 | 1994-10-24 | United States Biochemical Corporation | Use of exonuclease in dna sequencing |
US6379940B2 (en) * | 2000-03-21 | 2002-04-30 | Usb Corporation | Stable composition comprising a nuclease and a phosphatase |
-
2004
- 2004-08-18 GB GBGB0418388.5A patent/GB0418388D0/en not_active Ceased
-
2005
- 2005-08-17 WO PCT/GB2005/003211 patent/WO2006018632A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2006018632A2 (en) | 2006-02-23 |
WO2006018632A3 (en) | 2006-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006018632A3 (en) | Cell therapy with exo 1 | |
UA89957C2 (en) | Chimeric adenoviruses for use in cancer treatment | |
WO2005100998A3 (en) | Membrane markers for use in cancer diagnosis and therapy | |
IL190796A0 (en) | Compositions and their uses for gene therapy of bone conditions | |
WO2004113571A3 (en) | Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis | |
RS20150135A1 (en) | Treatment with anti-vegf antibodies | |
WO2005030121A3 (en) | Compounds, compositions and methods | |
ATE536376T1 (en) | HUMAN BINDING MOLECULE AGAINST CD1A | |
IL184617A0 (en) | Dr5 antibodies and uses thereof | |
MX349188B (en) | Sns-595 and methods of using the same. | |
MXPA05005398A (en) | Target for therapy of cognitive impairment. | |
WO2006060680A3 (en) | Mda-7 protein variants having antiproliferative activity | |
WO2007064945A3 (en) | Cancer therapies and pharmaceutical compositions used therein | |
HK1145070A1 (en) | Therapeutic use of a growth factor, metrnl | |
MXPA05012421A (en) | Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents. | |
WO2004106495A3 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer | |
WO2004098377A3 (en) | Methods and compositions for diagnosis and therapy of parkin-associated disorders | |
WO2006027693A8 (en) | Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis | |
WO2003076610A3 (en) | Variants of human kallikrein-2 and kallikrein-3 and uses thereof | |
HK1074840A1 (en) | Novel dithiolopyrrolones with therapeutic activity | |
TW200716749A (en) | Interferon-beta gene therapy using an improved, regulated expression system | |
MX2012000541A (en) | Therapeutic peptides, polypeptides ans nucleic acid sequences. | |
ATE537838T1 (en) | COMBINATION THERAPY WITH KLORETAZINE(TM) | |
IL174134A0 (en) | Use of a protein in the preparation of a medicament for treatment of fibrotic diseases | |
WO2006105343A3 (en) | Dkkl-i splice product modulators for cancer diagnosis and therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |